The US Association for Accessible Medicines has welcomed the prospect of collaborating with the administration of US president-elect Joe Biden on policies to bolster the off-patent industry, insisting that there is “more to be done” to improve the use of generics and biosimilars.
“The AAM looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to...




